Table 2 Results of overall and stratifed meta-analysis
Genetic model | Group/subgroup | Studies | Heterogeneity test | Statistical model | Test for overall effect | ||
|---|---|---|---|---|---|---|---|
I2 (%) | Phet | OR (95% CI) | P | ||||
CC vs. TT | Overall | 79 | 57.4 | 0 | R | 1.01(0.93–1.11) | 0.799 |
PB | 42 | 58.6 | 0 | R | 1.01(0.92–1.11) | 0.870 | |
HB | 37 | 57.3 | 0 | R | 1.01(0.83–1.23) | 0.915 | |
Asian | 32 | 55.8 | 0 | R | 1.10(0.88–1.37) | 0.403 | |
Caucasian | 33 | 65.9 | 0 | R | 1.03(0.90–1.18) | 0.652 | |
Taqman | 41 | 63.9 | 0 | R | 1.08(0.94–1.23) | 0.272 | |
PCR-RFLP | 23 | 60.4 | 0 | R | 0.94(0.74–1.20) | 0.615 | |
PCR-PIRA | 5 | 0 | 0.802 | F | 0.83(0.56–1.23) | 0.345 | |
bladder cancer | 4 | 13.1 | 0.327 | F | 0.74(0.55–0.99) | 0.040 | |
breast cancer | 13 | 53.5 | 0.012 | R | 1.01(0.87–1.17) | 0.939 | |
cervical cancer | 2 | 82.6 | 0.016 | R | 1.04(0.11–9.53) | 0.971 | |
colorectal cancer | 12 | 17.7 | 0.270 | F | 0.95(0.86–1.06) | 0.340 | |
esophageal cancer | 4 | 61.1 | 0.052 | R | 1.30(0.72–2.33) | 0.390 | |
gallbladder cancer | 2 | 0 | 0.532 | F | 1.28(0.78–2.12) | 0.326 | |
gastric cancer | 4 | 52.4 | 0.098 | R | 1.34(0.85–2.13) | 0.210 | |
HCC | 2 | 59.9 | 0.114 | F | 1.54(0.88–2.70) | 0.128 | |
laryngeal cancer | 2 | 67.3 | 0.080 | R | 0.98(0.35–2.75) | 0.973 | |
lung cancer | 11 | 80.5 | 0 | R | 0.97(0.65–1.45) | 0.883 | |
nasopharyngeal cancer | 3 | 56.1 | 0.103 | F | 0.59(0.40–0.86) | 0.007 | |
oral cancer | 3 | 0 | 0.404 | F | 0.68(0.40–1.16) | 0.158 | |
ovarian cancer | 2 | 51.6 | 0.151 | F | 0.84(0.64–1.10) | 0.205 | |
prostate cancer | 6 | 42.8 | 0.120 | F | 1.10(0.95–1.28) | 0.192 | |
skin cancer | 3 | 42.6 | 0.175 | F | 1.51(1.02–2.25) | 0.041 | |
TC vs. TT | Overall | 79 | 33.1 | 0.003 | R | 0.99(0.95–1.03) | 0.462 |
PB | 42 | 28.4 | 0.047 | R | 1.00(0.96–1.04) | 0.908 | |
HB | 37 | 37.7 | 0.012 | R | 0.96(0.88–1.04) | 0.303 | |
Asian | 32 | 43.4 | 0.005 | R | 0.98(0.90–1.07) | 0.675 | |
Caucasian | 33 | 23.1 | 0.119 | F | 0.99(0.95–1.04) | 0.679 | |
Taqman | 41 | 36.2 | 0.012 | R | 1.03(0.97–1.09) | 0.313 | |
PCR-RFLP | 23 | 11.6 | 0.303 | F | 0.97(0.90–1.05) | 0.494 | |
PCR-PIRA | 5 | 50.4 | 0.089 | R | 0.78(0.61–0.99) | 0.037 | |
bladder cancer | 4 | 49.4 | 0.115 | F | 0.75(0.62–0.90) | 0.002 | |
breast cancer | 13 | 0 | 0.540 | F | 0.99(0.94–1.04) | 0.676 | |
cervical cancer | 2 | 0 | 0.604 | F | 1.00(0.74–1.37) | 0.980 | |
colorectal cancer | 12 | 3.8 | 0.408 | F | 0.97(0.90–1.03) | 0.305 | |
esophageal cancer | 4 | 0 | 0.772 | F | 1.35(1.10–1.66) | 0.004 | |
gallbladder cancer | 2 | 41.6 | 0.191 | F | 1.05(0.80–1.38) | 0.706 | |
gastric cancer | 4 | 57.2 | 0.071 | R | 1.10(0.89–1.36) | 0.389 | |
HCC | 2 | 52.2 | 0.148 | F | 1.11(0.85–1.44) | 0.467 | |
laryngeal cancer | 2 | 0 | 0.542 | F | 0.88(0.69–1.13) | 0.322 | |
lung cancer | 11 | 51.3 | 0.025 | R | 0.90(0.79–1.03) | 0.140 | |
nasopharyngeal cancer | 3 | 33.3 | 0.223 | F | 0.84(0.67–1.06) | 0.135 | |
oral cancer | 3 | 0 | 0.867 | F | 0.88(0.69–1.12) | 0.307 | |
ovarian cancer | 2 | 14.7 | 0.279 | F | 1.02(0.86–1.20) | 0.855 | |
prostate cancer | 6 | 3.1 | 0.397 | F | 1.02(0.93–1.12) | 0.662 | |
skin cancer | 3 | 0 | 0.806 | F | 1.20(0.93–1.54) | 0.154 | |
(CC + TC) vs. TT | Overall | 79 | 50.0 | 0 | R | 0.99(0.95–1.04) | 0.644 |
PB | 42 | 46.4 | 0.001 | R | 1.00(0.95–1.05) | 0.992 | |
HB | 37 | 53.9 | 0 | R | 0.97(0.88–1.06) | 0.490 | |
Asian | 32 | 57.0 | 0 | R | 0.99(0.90–1.10) | 0.892 | |
Caucasian | 33 | 51.5 | 0 | R | 1.01(0.95–1.08) | 0.775 | |
Taqman | 41 | 53.3 | 0 | R | 1.04(0.97–1.11) | 0.249 | |
PCR-RFLP | 23 | 43.4 | 0.015 | R | 0.98(0.88–1.10) | 0.758 | |
PCR-PIRA | 5 | 48.8 | 0.099 | R | 0.79(0.63–0.98) | 0.035 | |
bladder cancer | 4 | 52.9 | 0.095 | R | 0.73(0.53–1.00) | 0.052 | |
breast cancer | 13 | 19.0 | 0.251 | F | 1.00(0.95–1.04) | 0.877 | |
cervical cancer | 2 | 0 | 0.862 | F | 0.98(0.73–1.32) | 0.909 | |
colorectal cancer | 12 | 4.3 | 0.403 | F | 0.96(0.90–1.03) | 0.237 | |
esophageal cancer | 4 | 0 | 0.414 | F | 1.33(1.10–1.63) | 0.004 | |
gallbladder cancer | 2 | 2.2 | 0.312 | F | 1.08(0.84–1.40) | 0.557 | |
gastric cancer | 4 | 65.6 | 0.033 | R | 1.13(0.90–1.42) | 0.300 | |
HCC | 2 | 67.1 | 0.081 | R | 1.08(0.66–1.77) | 0.764 | |
laryngeal cancer | 2 | 7.3 | 0.299 | F | 0.87(0.68–1.10) | 0.238 | |
lung cancer | 11 | 72.7 | 0 | R | 0.92(0.78–1.10) | 0.363 | |
nasopharyngeal cancer | 3 | 47.0 | 0.152 | F | 0.79(0.64–0.98) | 0.030 | |
oral cancer | 3 | 0 | 0.856 | F | 0.85(0.67–1.08) | 0.180 | |
ovarian cancer | 2 | 0 | 0.565 | F | 0.98(0.84–1.14) | 0.784 | |
prostate cancer | 6 | 21.0 | 0.275 | F | 1.04(0.95–1.13) | 0.408 | |
skin cancer | 3 | 0 | 0.979 | F | 1.25(0.99–1.59) | 0.063 | |
CC vs. (TC + TT) | Overall | 79 | 52.6 | 0 | R | 1.01(0.94–1.09) | 0.779 |
PB | 42 | 53.2 | 0 | R | 1.01(0.93–1.09) | 0.831 | |
HB | 37 | 53.3 | 0 | R | 1.01(0.85–1.21) | 0.876 | |
Asian | 32 | 52.9 | 0 | R | 1.07(0.86–1.32) | 0.500 | |
Caucasian | 33 | 58.5 | 0 | R | 1.02(0.91–1.14) | 0.715 | |
Taqman | 41 | 60.9 | 0 | R | 1.05(0.94–1.18) | 0.400 | |
PCR-RFLP | 23 | 55.3 | 0.001 | R | 0.94(0.76–1.17) | 0.572 | |
PCR-PIRA | 5 | 0 | 0.845 | F | 0.88(0.59–1.30) | 0.510 | |
bladder cancer | 4 | 25.9 | 0.256 | F | 0.78(0.61–1.01) | 0.061 | |
breast cancer | 13 | 53.4 | 0.012 | R | 1.01(0.88–1.16) | 0.884 | |
cervical cancer | 2 | 83.8 | 0.013 | R | 1.04(0.11–10.14) | 0.972 | |
colorectal cancer | 12 | 19.1 | 0.256 | F | 0.97(0.88–1.06) | 0.471 | |
esophageal cancer | 4 | 60.8 | 0.054 | R | 1.12(0.64–1.95) | 0.695 | |
gallbladder cancer | 2 | 13.5 | 0.282 | F | 1.13(0.71–1.80) | 0.615 | |
gastric cancer | 4 | 27.8 | 0.245 | F | 1.30(1.00–1.68) | 0.052 | |
HCC | 2 | 42.5 | 0.187 | F | 1.51(0.87–2.61) | 0.141 | |
laryngeal cancer | 2 | 62.6 | 0.102 | F | 0.80(0.51–1.26) | 0.338 | |
lung cancer | 11 | 75.4 | 0 | R | 0.99(0.70–1.38) | 0.932 | |
nasopharyngeal cancer | 3 | 46.9 | 0.152 | F | 0.65(0.46–0.94) | 0.020 | |
oral cancer | 3 | 0 | 0.388 | F | 0.71(0.42–1.18) | 0.182 | |
ovarian cancer | 2 | 65.5 | 0.088 | R | 0.75(0.42–1.34) | 0.336 | |
prostate cancer | 6 | 44.6 | 0.108 | F | 1.11(0.97–1.27) | 0.137 | |
skin cancer | 3 | 57.6 | 0.095 | R | 1.01(0.94–1.09) | 0.454 | |
C allele vs. T allele | Overall | 79 | 62.0 | 0 | R | 1.00(0.96–1.04) | 0.921 |
PB | 42 | 59.9 | 0 | R | 1.01(0.96–1.05) | 0.810 | |
HB | 37 | 64.8 | 0 | R | 0.98(0.90–1.07) | 0.656 | |
Asian | 32 | 66.4 | 0 | R | 1.00(0.91–1.09) | 0.956 | |
Caucasian | 33 | 66.9 | 0 | R | 1.02(0.96–1.08) | 0.573 | |
Taqman | 41 | 66.5 | 0 | R | 1.04(0.98–1.10) | 0.239 | |
PCR-RFLP | 23 | 61.4 | 0 | R | 0.99(0.89–1.09) | 0.794 | |
PCR-PIRA | 5 | 39.9 | 0.155 | F | 0.84(0.74–0.96) | 0.010 | |
bladder cancer | 4 | 57.4 | 0.070 | R | 0.76(0.60–0.96) | 0.020 | |
breast cancer | 13 | 47.8 | 0.028 | R | 1.00(0.94–1.06) | 0.938 | |
cervical cancer | 2 | 9.5 | 0.293 | F | 0.95(0.75–1.22) | 0.699 | |
colorectal cancer | 12 | 12.8 | 0.319 | F | 0.97(0.93–1.02) | 0.222 | |
esophageal cancer | 4 | 56.6 | 0.075 | R | 1.21(0.96–1.52) | 0.100 | |
gallbladder cancer | 2 | 0 | 0.759 | F | 1.07(0.88–1.31) | 0.496 | |
gastric cancer | 4 | 67.7 | 0.026 | R | 1.14(0.94–1.38) | 0.195 | |
HCC | 2 | 73.4 | 0.052 | R | 1.10(0.71–1.71) | 0.658 | |
laryngeal cancer | 2 | 47.3 | 0.168 | F | 0.88(0.73–1.06) | 0.183 | |
lung cancer | 11 | 83.0 | 0 | R | 0.96(0.82–1.14) | 0.661 | |
nasopharyngeal cancer | 3 | 54.1 | 0.113 | F | 0.80(0.68–0.94) | 0.007 | |
oral cancer | 3 | 0 | 0.669 | F | 0.85(0.70–1.03) | 0.106 | |
ovarian cancer | 2 | 0 | 0.850 | F | 0.95(0.85–1.07) | 0.428 | |
prostate cancer | 6 | 44.2 | 0.111 | F | 1.05(0.98–1.12) | 0.188 | |
skin cancer | 3 | 0 | 0.589 | F | 1.21(1.02–1.45) | 0.031 | |